Introduction: Hematological toxicity and infectious complications are both common and
substantially contribute to non-relapse mortality of CAR T-cell therapy. The recently …

Abstract Background BCMA-directed CAR T-cell therapy (CAR-T) has altered the treatment
landscape of relapsed/refractory (r/r) multiple myeloma, but is hampered by unique side …

Introduction: Chimeric antigen receptor T-cell (CAR-T) therapies targeting B-cell maturation
antigen (BCMA) have been shown to be effective in the treatment of patients (pts) with …

Background: Novel treatment approaches including chimeric antigen receptor (CAR) T
therapy and bispecific antibodies (Abs) have shown remarkable efficacy in highly pretreated …

BCMA-targeting CAR-T cells used in multiple myeloma (MM) are rapidly becoming a
mainstay in the treatment of relapsed/refractory (RR) disease, and CAR-T cell expansion …

• Background: Encouraging results are seen from several early phase clinical trials on the
cellular immunotherapy based on chimeric antigen receptor (CAR)-engineered T (CAR-T) …

Purpose: B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy
results in high remission rates in patients with relapsed/refractory (R/R) multiple myeloma …

HBI0101 is an academic chimeric antigen receptor T (CART) targeted to BCMA for the
treatment of relapsed and refractory multiple myeloma (RRMM) and light chain amyloidosis …

Introduction: Risks of B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR-T)
therapy for patients with multiple myeloma (MM) include cytokine release syndrome (CRS) …

Introduction: Chimeric antigen receptor (CAR) T cell therapy directed against B-cell
maturation antigen (BCMA) has shown promising results for the treatment of relapsed …